ASCAT 2023 | STArT trial: arginine in the treatment of SCD pain
Andrew Campbell, MD, Children’s National Medical Center, George Washington University School of Medicine and Health Sciences, Washington, DC, provides insights into the ongoing Sickle Cell Disease Treatment with Arginine Therapy (START) trial (NCT04839354). This trial investigates the efficacy of arginine in mitigating pain crises, thereby reducing hospitalization durations. Dr Campbell also outlines ongoing trials assessing the efficacy of citrulline, a precursor to arginine, with the same primary endpoint. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
